Sanctuary Advisors LLC Buys 450 Shares of Illumina, Inc. (NASDAQ:ILMN)

Sanctuary Advisors LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 2.0% in the third quarter, Holdings Channel.com reports. The firm owned 22,778 shares of the life sciences company’s stock after purchasing an additional 450 shares during the quarter. Sanctuary Advisors LLC’s holdings in Illumina were worth $3,192,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Industrial Alliance Investment Management Inc. bought a new stake in shares of Illumina in the second quarter worth $34,000. TD Private Client Wealth LLC grew its position in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after buying an additional 141 shares during the last quarter. Massmutual Trust Co. FSB ADV increased its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after buying an additional 168 shares during the period. Itau Unibanco Holding S.A. bought a new position in shares of Illumina during the second quarter worth about $61,000. Finally, Private Trust Co. NA lifted its stake in shares of Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Leerink Partners increased their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. UBS Group boosted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Morgan Stanley reissued an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Finally, Robert W. Baird upped their target price on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Stock Down 0.9 %

ILMN opened at $143.12 on Wednesday. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The firm has a market capitalization of $22.70 billion, a P/E ratio of -14.37 and a beta of 1.11. The company’s 50-day moving average is $144.42 and its 200 day moving average is $129.20. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 EPS. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.